Published in J Immunol on March 31, 2014
Targeting natural killer cells in cancer immunotherapy. Nat Immunol (2016) 1.06
NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer (2015) 1.04
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity (2016) 0.96
Dendritic Cell-Secreted Cytotoxic T-Lymphocyte-Associated Protein-4 Regulates the T-cell Response by Downmodulating Bystander Surface B7. Stem Cells Dev (2016) 0.80
HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. Eur J Immunol (2015) 0.76
Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy. Exp Mol Med (2017) 0.75
Acute Malaria Induces PD1+CTLA4+ Effector T Cells with Cell-Extrinsic Suppressor Function. PLoS Pathog (2016) 0.75
Modeling Natural Killer Cell Targeted Immunotherapies. Front Immunol (2017) 0.75
Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance. Front Immunol (2017) 0.75
Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke. Brain (2011) 1.95
Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med (2012) 1.86
Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol (2012) 1.56
Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells. Blood (2008) 1.56
Harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy. PLoS One (2008) 1.47
Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res (2011) 1.41
Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res (2008) 1.40
Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44. J Immunol (2011) 1.37
The TREM-1/DAP12 pathway. Immunol Lett (2007) 1.33
Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. J Virol (2009) 1.20
Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection. J Exp Med (2005) 1.18
IL-12-producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell expansion. J Clin Invest (2014) 1.17
Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int J Cancer (2008) 1.12
Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int J Cancer (2009) 1.11
Modulation of NKp30- and NKp46-mediated natural killer cell responses by poxviral hemagglutinin. PLoS Pathog (2011) 1.11
Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS One (2012) 1.08
Natural killer cells and solid tumors. J Innate Immun (2011) 1.07
Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood (2013) 1.06
Non-T cell activation linker (NTAL) negatively regulates TREM-1/DAP12-induced inflammatory cytokine production in myeloid cells. J Immunol (2007) 1.05
Memory of infections: an emerging role for natural killer cells. PLoS Pathog (2013) 1.00
Activation of the Hippo pathway by CTLA-4 regulates the expression of Blimp-1 in the CD8+ T cell. Proc Natl Acad Sci U S A (2012) 0.98
Regulation of triggering receptor expressed on myeloid cells 1 expression on mouse inflammatory monocytes. Immunology (2009) 0.97
Surface CD107a/LAMP-1 protects natural killer cells from degranulation-associated damage. Blood (2013) 0.96
Cutting edge: the AP-1 subunit JunB determines NK cell-mediated target cell killing by regulation of the NKG2D-ligand RAE-1epsilon. J Immunol (2006) 0.95
Identification of CLEC12B, an inhibitory receptor on myeloid cells. J Biol Chem (2007) 0.93
Regulatory T cells control macrophage accumulation and activation in lymphoma. Int J Cancer (2010) 0.91
Btk is a positive regulator in the TREM-1/DAP12 signaling pathway. Blood (2011) 0.88
The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma. Clin Cancer Res (2006) 0.88
Shaping of NK cell responses by the tumor microenvironment. Cancer Microenviron (2012) 0.87
NF-κ B-dependent upregulation of ICAM-1 by HPV16-E6/E7 facilitates NK cell/target cell interaction. Int J Cancer (2011) 0.83
Toward the next generation of NK cell-based adoptive cancer immunotherapy. Oncoimmunology (2013) 0.80
Mimitin - a novel cytokine-regulated mitochondrial protein. BMC Cell Biol (2009) 0.80
Host-derived interleukin-1alpha is important in determining the immunogenicity of 3-methylcholantrene tumor cells. J Immunol (2009) 0.80
Organ-specific cellular requirements for in vivo dendritic cell generation. J Immunol (2011) 0.78
Exploiting natural killer cells for therapy of melanoma. J Dtsch Dermatol Ges (2015) 0.76
Correction: harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy. PLoS One (2015) 0.75
NK cells--versatile tools for viral defense and cancer treatment. Eur J Immunol (2013) 0.75
Chronic liver inflammation and hepatocellular carcinogenesis are independent of S100A9. Int J Cancer (2014) 0.75